Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

Key Inclusion Criteria:

1. Provide written informed consent prior to performing study procedures

2. Hospitalized.

3. Male or female ≥18 years of age

4. Positive for severe acute respiratory syndrome coronavirus 2

5. Presence of symptoms of lower respiratory tract infection (LRTI) including at least 1
of the following: fever, cough, sore throat, malaise, headache, muscle pain, or more
significant lower respiratory tract symptoms, including shortness of breath

6. At least 1 of the following: respiratory rate (RR) ≥20 breaths per minute, room air
oxygen saturation (SpO2) <98%, requirement for supplemental oxygen, heart rate (HR)
≥90 beats per minute, or temperature >38.3°C

7. Women of childbearing potential must agree to abstinent or use at least 1 form of
contraception not including hormonal contraception from the day of screening through
Day 30

Key Exclusion Criteria:

1. Hospitalized but no longer requires ongoing inpatient care (i.e., discharge is
anticipated in ≤24 hours)

2. Patient is not anticipated to survive >48 hours OR is under palliative care

3. Evidence of critical illness, defined by at least 1 of the following:

- Respiratory failure requiring at least 1 of the following:

1. Endotracheal intubation and mechanical ventilation, oxygen delivered by high
flow nasal cannula

2. Noninvasive positive pressure ventilation (NIPVV), OR

3. Extracorporeal membrane oxygenation (ECMO) or clinical diagnosis of
respiratory failure

- Shock (defined by systolic blood pressure (BP) <90 mm Hg, or diastolic blood
pressure (BP) <60 mm Hg or requiring vasopressors), OR

- Multi-organ dysfunction/failure

4. Severe central nervous system (CNS) conditions

5. Chronic kidney disease requiring dialysis

6. Known allergy to the study drug or salicylate containing medications.

7. Suspected and/or confirmed pregnancy or breastfeeding

8. Current or planned participation in any other clinical trial of a treatment being
developed under a US investigational new drug (IND) or emergency use authorization
(EUA).

9. Patients receiving chemotherapeutic agents and/or immunomodulators (including
monoclonal antibodies (Mabs) or plasma transfusions) for chronic disease conditions.